Lin Yusheng, Jiang Li, He Qiaojun, Yuan Meng, Cao Ji
Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China; The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China; Cancer Center of Zhejiang University, Hangzhou, China.
Biomed Pharmacother. 2022 May;149:112869. doi: 10.1016/j.biopha.2022.112869. Epub 2022 Mar 28.
Organoids are in vitro simplified and miniature microcosms of internal organs, which have aroused great interest in tissue development, multiple disease models, clinical diagnosis, as well as high-throughput drug screening and personalized medicine and so on. The success of physiology-related organoid culture has greatly advanced the translational medicine research in the field of cancer treatment, which was once troubled by the inconsistency between two-dimensional (2D) cell culture and in vivo studies. Especially in recent years, the success rate of establish an organoid has been greatly improved, and the types of organoids have been gradually enriched. Moreover, the utilizing of some the cutting-edge technologies, including gene editing technology such as CRISPR-Cas9, the scope of application of organoid is broadened. In this review, we discuss the latest progress and applications of organoids, and also outline the potential challenges of organoids for future improvement.
类器官是体内器官的体外简化和微型缩影，在组织发育、多种疾病模型、临床诊断以及高通量药物筛选和个性化医疗等方面引起了极大的兴趣。与生理学相关的类器官培养的成功极大地推动了癌症治疗领域的转化医学研究，该领域曾因二维（2D）细胞培养与体内研究之间的不一致而受到困扰。特别是近年来，类器官的建立成功率有了很大提高，类器官的类型也逐渐丰富。此外，包括CRISPR-Cas9等基因编辑技术在内的一些前沿技术的应用，拓宽了类器官的应用范围。在本综述中，我们讨论了类器官的最新进展和应用，并概述了类器官未来改进面临的潜在挑战。
